EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells

The Enhancer of Zeste 2 (EZH2) protein has been reported to stimulate cell growth in some cancers and is therefore considered to represent an interesting new target for therapeutic intervention. Here, we investigated a possible role of EZH2 for the growth control of colon cancer cells. RNA interference (RNAi)-mediated intracellular EZH2 depletion led to cell cycle arrest of colon carcinoma cells at the G1/S transition. This was associated with a reduction of cell numbers upon transient transfection of synthetic EZH2-targeting siRNAs and with inhibition of their colony formation capacity upon stable expression of vector-borne siRNAs. We furthermore tested whether EZH2 may repress the growth-inhibitory p27 gene, as reported for pancreatic cancer. However, expression analyses of colon cancer cell lines and colon cancer biopsies did not reveal a consistent correlation between EZH2 and p27 levels. Moreover, EZH2 depletion did not re-induce p27 expression in colon cancer cells, indicating that p27 repression by EZH2 may be cell- or tissue-specific. Whole genome transcriptome analyses identified cellular genes affected by EZH2 depletion in colon cancer cell lines. They included several cancer-associated genes linked to cellular proliferation or invasion, such as Dag1, MageD1, SDC1, Timp2, and Tob1. In conclusion, our results demonstrate that EZH2 depletion blocks the growth of colon cancer cells. These findings might provide benefits for the treatment of colon cancer.

[1]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[2]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[3]  Y. Zeng,et al.  EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. , 2010, Carcinogenesis.

[4]  A. Tarakhovsky,et al.  Ezh2, the histone methyltransferase of PRC2, regulates the balance between self-renewal and differentiation in the cerebral cortex , 2010, Proceedings of the National Academy of Sciences.

[5]  G. Calin,et al.  Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.

[6]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[7]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[8]  D. Hommes,et al.  The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer , 2010, Carcinogenesis.

[9]  F. Liu,et al.  EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. , 2010, World journal of gastroenterology.

[10]  Qiang Yu,et al.  Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression , 2010, Cell Death and Differentiation.

[11]  David Heber,et al.  Limitations of MTT and MTS-Based Assays for Measurement of Antiproliferative Activity of Green Tea Polyphenols , 2010, PloS one.

[12]  J. Licht,et al.  Deregulation of H3K27 methylation in cancer , 2010, Nature Genetics.

[13]  G. S. Winkler,et al.  The mammalian anti‐proliferative BTG/Tob protein family , 2010, Journal of cellular physiology.

[14]  Anja Schindler,et al.  A Direct Phenotypic Comparison of siRNA Pools and Multiple Individual Duplexes in a Functional Assay , 2009, PloS one.

[15]  C. Shou,et al.  PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin β1-ERK1/2 and-MMP2 signaling , 2009, Molecular Cancer.

[16]  M. Scheffner,et al.  Oncogenic human papillomaviruses block expression of the B‐cell translocation gene‐2 tumor suppressor gene , 2009, International journal of cancer.

[17]  R. Tuma.  Epigenetic therapies move into new territory, but how exactly do they work? , 2009, Journal of the National Cancer Institute.

[18]  Huidong Shi,et al.  Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.

[19]  K. Gravdal,et al.  Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis , 2009, British Journal of Cancer.

[20]  Yang Zhang,et al.  MAGE-D1 inhibits proliferation, migration and invasion of human breast cancer cells. , 2009, Oncology reports.

[21]  G. Hannon,et al.  Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells , 2009, Cell.

[22]  F. Hoppe-Seyler,et al.  Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. , 2008, Cancer research.

[23]  J. Simon,et al.  Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.

[24]  V. Bilim,et al.  Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2 , 2008, Clinical Cancer Research.

[25]  T. Fujita,et al.  Regulation of Skp2-p27 axis by the Cdh1/anaphase-promoting complex pathway in colorectal tumorigenesis. , 2008, The American journal of pathology.

[26]  H. Zentgraf,et al.  The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells , 2008, International journal of cancer.

[27]  Ludger Hengst,et al.  The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy , 2008, Nature Reviews Cancer.

[28]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[29]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[30]  T. Muley,et al.  The anti-apoptotic livin gene is an important determinant for the apoptotic resistance of non-small cell lung cancer cells. , 2006, Lung cancer.

[31]  D. Saur,et al.  IKKα controls p52/RelB at the skp2 gene promoter to regulate G1‐ to S‐phase progression , 2006, The EMBO journal.

[32]  L. Bystrykh,et al.  The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. , 2006, Blood.

[33]  T. Ochiya,et al.  Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K. Mimori,et al.  Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[35]  T. Utsunomiya,et al.  Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma , 2005, British Journal of Cancer.

[36]  C. Meijer,et al.  Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. , 2004, The American journal of pathology.

[37]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[38]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[39]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Hengstermann,et al.  siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells , 2003, Oncogene.

[41]  G. Rossi,et al.  Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. , 2003, The American journal of pathology.

[42]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[43]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[44]  G. Landberg,et al.  Prognostic significance of p27Kip1 expression in colorectal cancer: a clinico‐pathological characterization , 1999, The Journal of pathology.

[45]  F. Hoppe-Seyler,et al.  Functional p53 protein in human papillomavirus-positive cancer cells. , 1995, Oncogene.

[46]  R. Sanderson,et al.  Expression of syndecan-1 inhibits cell invasion into type I collagen. , 1994, The Journal of biological chemistry.

[47]  J. Watson,et al.  The MTT assay underestimates the growth inhibitory effects of interferons. , 1989, British Journal of Cancer.

[48]  M. Braga,et al.  Exploratory Data Analysis , 2018, Encyclopedia of Social Network Analysis and Mining. 2nd Ed..

[49]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[50]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[51]  M. Fox,et al.  A model for the computer analysis of synchronous DNA distributions obtained by flow cytometry. , 1980, Cytometry.

[52]  M. Hung,et al.  CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells , 2011, Nature Cell Biology.

[53]  P. Linsley,et al.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.

[54]  I. Cree,et al.  Comparison of MTT and ATP-based assays for the measurement of viable cell number. , 1995, Journal of bioluminescence and chemiluminescence.

[55]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .